Abstract
The objectives of this study were to evaluate the effect of the use of yeast fermentation products (YFP) on growth, hormone concentration, and gut permeability in dairy calves. One hundred and twenty heifers were randomly assigned to one of three treatments: control group with no YFP supplementation (C), Saccharomyces cerevisiae fermentation products (SCFP) supplementation (1 g/head/d of SmartCare [Diamond V] in the milk and 0.7% on dry matter basis of NutriTek [Diamond V] on the starter feed), or Aspergillus oryzae fermentation extracts (AOFE) supplementation (3 g/head/d of LXtract1224 [Biozyme Inc.] in the milk). All calves received 6 L/d of pasteurized milk and had ad libitum access to water and dry feed along the study. Body weight (BW) was recorded at birth and on days 14, 30, and 45 and at weaning. Dry feed (starter) offered was measured daily and refusals twice a week to obtain starter intake (SI). Diarrhea events were recorded daily and fecal scores were classified by using a four-point scale. Blood was sampled on days 7 and 14 for plasma glucose, nonesterified fatty acids (NEFA), insulin, and IL-1β concentrations. Lactulose and D-mannitol were included in the morning feeding of day 14 and blood samples were taken an hour after feeding for assessment of intestinal permeability. On day 14, blood samples were taken for plasma glucagon-like peptide 2 (GLP-2) concentration. On day 30, fecal samples were collected for measurements of Salmonella and Escherichia coli concentration on feces. No treatment differences (P ≥ 0.13) were found for BW or SI. There was a time by treatment difference (P = 0.01) in average daily gain (ADG) on day 45 where C animals had a greater ADG when compared with SCFP and AOFE. Diarrhea incidence did not change between treatments (P = 0.97) and Salmonella and E. coli were not found in feces. There were no differences (P > 0.60) between treatments for plasma GLP-2, glucose, insulin, lactulose, nor D-mannitol concentrations. There was a time by treatment tendency (P = 0.06) for NEFA concentration which tended to be greater on day 7 for C and AOFE when compared with day 14. Plasma IL-1β concentration showed a treatment tendency which tended (P = 0.06) to be greater for SCFP when compared with C. Under the current conditions, supplementation with YFP did not improve performance parameters. Plasma GLP-2 concentration, intestinal permeability, and plasma metabolites did not differ after yeast fermentation products supplementation.